[The effect of air test and methylene blue perfusion test on detecting the quality of anastomosis during laparoscopic rectal cancer excision (Dixon)]

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Objective: To investigate the feasibility and safety of air test (AT) and methylene blue perfusion test (MBPT) to detect the quality of the anastomosis in laparoscopic rectal cancer excision (Dixon), and compare the two approaches.

Why It Was Studied

MBPT is carried out by surrounding clean sponges around anastomosis and injecting methylene blue solution into the rectum as like as AT.

The balloon catheter connected manometer,ensuring the pressure in rectum can reach 40 cmH(2)O during AT and MBPT.

Who Took Part

The study group was 28 patients.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

What Was Measured

Results: All 28 patients received both tests successfully with no adverse event.

MBPT Level 1 was detected in 15 cases, level 2 in 8 cases, level 3 in 5 cases.

Topics PubMed links to this paper include Anastomosis, Surgical, Anastomotic Leak, Laparoscopy, Methylene Blue, Rectal Neoplasms and Rectum.

Author keywords: Rectal cancer.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 28 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (Zhonghua yi xue za zhi), a journal based in China.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.